Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.8.0.1
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Accrued expenses:    
Professional fees $ 1,497 $ 1,625
Salaries, bonuses and related benefits 6,002 5,279
Accrued expenses - related party 107 95
Research and development 7,061 4,046
Dr. Falk Pharma milestone 3,059 3,059
Accrued royalties payable 1,091 1,411
Accrued coupon expense 735 0
Deferred coupon funding 1,516 1,087
Other 646 1,030
Total accrued expenses 21,714 17,632
Other long-term liabilities:    
Deferred rent 4,759 4,739
Total other long-term liabilities $ 4,759 $ 4,739